ArticleEuropean journal of nuclear medicine and molecular imaging2026
Diagnostic value of [
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
purposeTo evaluate the diagnostic performance of [18F]FAPI-04 PET/CT combined with LI-RADS-based contrast-enhanced CT/MRI for suspected monofocal HCC, with particular focus on characterizing indeterminate observations (LR-3, LR-4, and LR-M) and its impact on clinical management recommendations.
methodsPatients with monofocal liver lesions suspicious for HCC who underwent Ce-CT/MRI and [18F]FAPI-04 PET/CT were prospectively enrolled. For each lesion, LI-RADS category was assigned based on Ce-CT/MRI, and [18F]FAPI-04 uptake was assessed using the maximum standardized uptake value (SUVmax) and lesion-to-background ratio (LBR). Histopathology or ≥ 12-month imaging follow-up served as the reference standard. Exploratory optimal cutoff values for SUVmax and LBR were determined by receiver operating characteristic (ROC) curve to distinguish HCC from other hepatic observations. The diagnostic performances of LI-RADS-based Ce-CT/MRI, [18F]FAPI-04 PET/CT, and their combination were compared using McNemar’s test.
resultsThe cohort included 63 malignant (50 HCCs, 13 non-HCC malignancies) and 16 benign lesions. Both SUVmax and LBR were significantly higher in the LR-M category compared with LR-3, LR-4, and LR-5 (all P < 0.01), whereas uptake levels appeared comparable between LR-4 and LR-5. ROC analysis identified optimal cut-off values of SUVmax ≥3.7 for differentiating HCC from benign lesions (AUC 0.773) and LBR ≥ 6.9 for differentiating non-HCC malignancies from HCC (AUC 0.903). For LR-3/4 lesions < 30 mm, [18F]FAPI-04 PET/CT showed 77.8% sensitivity and 88.9% specificity for HCC diagnosis. For LR-M lesions < 30 mm, [18F]FAPI-04 PET/CT achieved 100% sensitivity and 100% specificity for identifying non-HCC malignancies. Overall, [18F]FAPI-04 PET/CT showed comparable diagnostic performance to LR-5 in sensitivity (66.0% vs. 62.0%), specificity (86.2% vs. 93.1%), and accuracy (both 73.4%). The combination of [18F]FAPI-04 PET/CT with LI-RADS significantly improved HCC detection sensitivity to 86.0% while maintaining 100% specificity.
conclusionsPreliminary results suggest that combining [18F]FAPI-04 PET/CT with LI-RADS-based Ce-CT/MRI significantly improves diagnostic accuracy for monofocal liver lesions suspicious for HCC.
trial registrationclinicaltrials.gov: NCT 05485792.
Indexed as
Identifiers
41857357What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.